UTHR
United Therapeutics Corporation
27
Building
United Therapeutics is poised for revaluation amid biotech rotation with high margins and low revenue growth.
The thesis
United Therapeutics operates in biotechnology with a gross margin of 8614.0% and a net margin of 4156.0%. The company's revenue growth is -1.9% YoY. The conviction score is 25/100, indicating a medium conviction tier. Analyst consensus rating is BUY, despite negative revenue growth, making the setup interesting.
Why now
The risk-off rotation macro signal is inactive, but a change in this signal could impact the stock. A 1.9% increase or decrease in revenue growth could be a catalyst.
What to watch
Revenue growth rate over the next quarter and any changes in the analyst consensus rating will be key indicators. A shift in the macro signal towards risk-off rotation will also be important to watch.
Key risks
Valuation risk is present with a P/E of 15.4x and DCF intrinsic value of $700. Execution risk is also a concern due to negative revenue growth.
Theme exposure
Healthcare, Biotech & Devices
DirectUnited Therapeutics Corporation operates in biotechnology. That places it inside the Healthcare, Biotech & Devices story.
This brief is generated from our intelligence layers. Treat it as a starting point, not a final word.
Market intelligence only. Not financial advice. Not a recommendation.